Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.68 USD | +1.78% | +13.34% | -22.83% |
04-15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
03-25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.83% | 2.24B | |
+25.47% | 48.09B | |
+46.90% | 40.62B | |
-3.19% | 40.43B | |
-6.20% | 28.36B | |
+9.54% | 24.89B | |
-20.00% | 19.01B | |
+28.83% | 12.09B | |
+0.86% | 11.88B | |
-1.53% | 11.8B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics, Regeneron Therapeutics Deliver Positive Early-Stage Data on ATTR Amyloidosis Treatment